Abhilash Jayaraj

Abhilash Jayaraj

Auto-generated profile, based on publicly available information

Abhilash Jayaraj

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Heliyon
Verified
Journal Article
Open access
DKDurgesh Kumar
Durgesh Kumar
MMMahendra Kumar Meena
Mahendra Kumar Meena
KKKamlesh Kumari
Kamlesh Kumari
RPRajan Patel
Rajan Patel
AJAbhilash Jayaraj
Abhilash Jayaraj
PSPRASHANT SINGH
PRASHANT SINGH
Literature reported that nsp3 of CHIKV is an important target for the designing of drug as it involves in the replication, survival etc. Herein, about eighteen million molecules available in the ZINC database are filtered against nsp3 using RASPD. Top five hit drug molecules were then taken from the total screened molecules (6988) from ZINC database. Then, a one pot-three components reaction is designed to get the pyrazolophthalazine and its formation was studied using DFT method. Authors created a library of 200 compounds using the product obtained in the reaction and filtered against nsp3 of CHIKV based on docking using iGEMDOCK, a computational tool. Authors have studied the best molecules after applying the the Lipinski's rule of five and bioactive score. Further, the authors took the best compound i.e. CMPD178 and performed the MD simulations and tdMD simulations with nsp3 protease using AMBER18. MD trajectories were studied to collect the information about the nsp3 of CHIKV with and without screened compound and then, MM-GBSA calculations were performed to calculate change in binding free energies for the formation of complex. The aim of the work is to find the potential candidate as promising inhibitor against nsp3 of CHIKV.

1 February 2021 in Endocrinology
Verified
Journal Article
Open access
PDF file
AJAbhilash Jayaraj
Abhilash Jayaraj
HSHeidi A Schwanz
Heidi A Schwanz
DSDaniel J Spencer
Daniel J Spencer
SBShalender Bhasin
Shalender Bhasin
JHJames A Hamilton
James A Hamilton
RJRavi Jasuja
Ravi Jasuja
Human serum albumin (HSA) acts as a carrier for testosterone, other sex hormones, fatty acids, and drugs. However, the dynamics of testosterone’s binding to HSA and the structure of its binding sites remain incompletely understood. Here, we characterize the dynamics of testosterone’s binding to HSA and the stoichiometry and structural location of the binding sites using 2-dimensional nuclear magnetic resonance (2D NMR), fluorescence spectroscopy, 4,4′-dianilino-1,1′-binaphthyl-5,5′-disulfonic acid dipotassium salt partitioning, and equilibrium dialysis, complemented by molecular modeling. 2D NMR studies showed that testosterone competitively displaced 18-[13C]-oleic acid from at least 3 known fatty acid binding sites on HSA that also bind many drugs. Binding isotherms of testosterone’s binding to HSA generated using fluorescence spectroscopy and equilibrium dialysis were nonlinear and the apparent dissociation constant varied with different concentrations of testosterone and HSA. The binding isotherms neither conformed to a linear binding model with 1:1 stoichiometry nor to 2 independent binding sites; the binding isotherms were most consistent with 2 or more allosterically coupled binding sites. Molecular dynamics studies revealed that testosterone’s binding to fatty acid binding site 3 on HSA was associated with conformational changes at site 6, indicating that residues in in these 2 distinct binding sites are allosterically coupled. There are multiple, allosterically coupled binding sites for testosterone on HSA. Testosterone shares these binding sites on HSA with free fatty acids, which could displace testosterone from HSA under various physiological states or disease conditions, affecting its bioavailability.

1 June 2021 in iScience
Verified
Journal Article
Open access
RJRavi Jasuja
Ravi Jasuja
DSDaniel Spencer
Daniel Spencer
AJAbhilash Jayaraj
Abhilash Jayaraj
LPLiming Peng
Liming Peng
MKMeenakshi Krishna
Meenakshi Krishna
SBShalender Bhasin
Shalender Bhasin
Sex-hormone-binding globulin (SHBG) regulates the transport and bioavailability of estradiol. The dynamics of estradiol's binding to SHBG are incompletely understood, although it is believed that estradiol binds to each monomer of SHBG dimer with identical affinity (Kd ∼2 nM). Contrary to the prevalent view, we show that estradiol's binding to SHBG is nonlinear, and the "apparent" Kd changes with varying estradiol and SHBG concentrations. Estradiol's binding to each SHBG monomer influences residues in the ligand-binding pocket of both monomers and differentially alters the conformational and energy landscapes of both monomers. Monomers are not energetically or conformationally equivalent even in fully bound state.

16 April 2020 in ChemistrySelect
Verified
Journal Article
Closed access
PDF file
DKDurgesh Kumar
Durgesh Kumar
PSPRASHANT SINGH
PRASHANT SINGH
AJAbhilash Jayaraj
Abhilash Jayaraj
VKVinod Kumar
Vinod Kumar
KKKamlesh Kumari
Kamlesh Kumari
VRVenkatesh Kumar Ramappa
Venkatesh Kumar Ramappa

26 January 2023 in Physical Chemistry Chemical Physics
Verified
Journal Article
Closed access
PDF file
SSShilpa Sharma
Shilpa Sharma
VTVijay Raj Tomar
Vijay Raj Tomar
AJAbhilash Jayaraj
Abhilash Jayaraj
SDShashank Deep
Shashank Deep
Pathology of superoxide dismutase 1 (SOD1) aggregation is linked to a neurodegenerative disease known as amyotrophic lateral sclerosis (ALS). Without suitable post-translational modifications (PTMs), the protein structure tends to become aggregation-prone. Understanding the role of PTMs and targeting the aggregation-prone SOD1 with small molecules can be used to design a strategy to inhibit its aggregation. Microsecond long molecular dynamics (MD) simulations followed by free energy surface (FES) analyses show that the loss of structure in the apo monomer happens locally and stepwise. Removing the disulfide bond from apoprotein leads to further instability in the zinc-binding loop, giving rise to non-native protein conformations. Further, it was found that these non-native conformations have a higher propensity to form a non-native dimer. We chose three structurally similar polyphenols based on their binding energies and investigated their impact on SOD1 aggregation kinetics. MD simulations of apo-SOD1SH/corkscrew fibril–polyphenol complexes were also carried out. The effect of polyphenols was seen on fibril elongation as well. Based on the experiments and MD simulation results, it can be inferred that the choice of inhibitors is influenced not only by the binding energy but also by dimer interface stabilization, the proclivity to form non-native dimers, the propensity to break fibrils, and the propensity to decrease the rate of elongation. The polyphenols with 3′ and 4′ hydroxyl groups are better inhibitors of SOD1 aggregation.

1 August 2020 in Chemical Engineering Science
Verified
Journal Article
Closed access
RBRuchika Bhat
Ruchika Bhat
RKRahul Kaushik
Rahul Kaushik
ASAnkita Singh
Ankita Singh
DDDebarati DasGupta
Debarati DasGupta
AJAbhilash Jayaraj
Abhilash Jayaraj
BJB. Jayaram
B. Jayaram